Company profile
ArriVent BioPharma, Inc.
NASDAQ:AVBPBiotechnology: Pharmaceutical Preparations
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07066657 | phase1 | recruiting | 2025-07-25 | 2028-03-01 | ArriVent BioPharma, Inc. | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors |
| NCT07755436 | phase1 | recruiting | 2026-07-23 | 2027-08-01 | ArriVent BioPharma, Inc. | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. |
| NCT05364073 | phase1 | active_not_recruiting | 2022-06-30 | 2025-06-03 | ArriVent BioPharma, Inc. | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations |
| NCT05607550 | phase3 | active_not_recruiting | 2023-06-01 | 2025-08-15 | ArriVent BioPharma, Inc. | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) |
| NCT07185997 | phase3 | recruiting | 2025-12-17 | 2029-02-01 | ArriVent BioPharma, Inc. | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations |
FDA applications (0)
No records yet.